CHENGDU, China, July 8 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., , a manufacturer and supplier of modernized traditional Chinese medicine (“TCM”) based in Chengdu, China, today declared a quarterly cash dividend to be paid to its common stock shareholders. The dividend of $0.025 will be paid to shareholders of record as of July 31, 2009, with the actual distribution occurring on or about September 10, 2009.
In addition, Tianyin will pay the quarterly dividend on its Series A Preferred Stock in cash to holders of record as of June 30, 2009. As of July 1, 2009, there are 6,826,500 shares of Series A Preferred Stock outstanding, which are convertible into shares of Tianyin’s common stock at $1.60 per share and mature in January 2011.
Dr. Jiang Guoqing, Tianyin’s Chairman and Chief Executive Officer, commented, “We appreciate the continued support of both our common and preferred shareholders. With a strong balance sheet, positive cash flow and a growing business, we have the resources to prudently manage our capital structure, while providing a current return to new and existing investors.”
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine (“TCM”) in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 33 modernized TCMs and 5 generic western medicines in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 47 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. Tianyin achieved revenue of approximately $33.5 million and net income of approximately $6 million in FY2008 ending June 30, 2008. For more information about Tianyin, please visit http://www.tianyinpharma.com .
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission.
CONTACT: Tianyin Pharmaceutical Co., Inc., Allen Tang, Ph.D., MBA,
Assistant to the CEO, +86-158-2122-5642, Allen.y.tang@gmail.com or HC
International, Mr. Matthew Hayden, +1-561-245-5155,
matt.hayden@hcinternational.net, for Tianyin Pharmaceutical Co., Inc.
Web site: http://www.hcinternational.net/
http://www.tianyinpharma.com/